Magenta Therapeutics, Inc.
USE OF ANTI-CD137 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY

Abstract:

The invention provides methods of using allogeneic cells in therapy by combining allogeneic cell therapy with anti-CD137 antibody drug conjugates (ADCs). Disclosed are methods of treating or preventing a host versus graft (HvG) rejection in a human subject receiving allogeneic cell therapy by administering to the human subject an anti-CD137 ADC.